The parasitic 68-mer peptide FhHDM-1 inhibits mixed granulocytic inflammation and airway hyperreactivity in experimental asthma - 06/06/18
Doi : 10.1016/j.jaci.2018.01.050
Akane Tanaka, BSc a, ∗, Venkata Sita Rama Raju Allam, MS Pharm b, ∗, Jennifer Simpson, BBiomedSc c, Natalia Tiberti, PhD a, Jenna Shiels, BSc d, e, Joyce To, BSc a, Maria Lund, PhD a, Valery Combes, PhD a, Sinead Weldon, PhD e, Cliff Taggart, PhD e, John P. Dalton, PhD d, Simon Phipps, PhD c, Maria B. Sukkar, PhD b, ∗, Sheila Donnelly, PhD a, ∗ 
a School of Life Sciences, Faculty of Science, The University of Technology Sydney, Ultimo, Australia
b Discipline of Pharmacy, Graduate School of Health, The University of Technology Sydney, Ultimo, Australia
c QIMR Berghofer Medical Research Institute, Herston, Australia
d School of Biological Sciences, Queen's University Belfast, Belfast, United Kingdom
e Airway Innate Immunity Group, Centre for Experimental Medicine, School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, Belfast, United Kingdom
| A.T. is supported by an Australian Government Research Training Program Scholarship. V.S.R.R.A. is supported by a University of Technology Sydney Postgraduate Research Scholarship. N.T. is supported by the Swiss National Science Foundation (grant P300PA_164715). C.T. and S.W. are supported by the Medical Research Council. J.P.D. is funded by grants from a European Research Council Advanced Grant (HELIVAC, 322725) and is a member of the Horizon 2020-funded Consortium PARAGONE. S.D. is funded by the National Health and Medical Research Council Australia (APP1087341). |
|
| Disclosure of potential conflict of interest: S. Donnelly and J. Dalton are both named inventors on a patent application covering the use of FhHDM-1 as an immune-modulating agent. The rest of the authors declare that they have no relevant conflicts of interest. |
© 2018
American Academy of Allergy, Asthma & Immunology. Tous droits réservés.
Vol 141 - N° 6
P. 2316-2319 - juin 2018 Retour au numéro
Article précédent
- Basophil Fc?RI expression is linked to time to omalizumab response in chronic spontaneous urticaria
- Gustavo Deza, Marta Bertolín-Colilla, Silvia Sánchez, Dulce Soto, Ramon M. Pujol, Ramon Gimeno, Ana M. Giménez-Arnau
- Non-posttransplant lymphoproliferative disorder malignancy after hematopoietic stem cell transplantation in patients with primary immunodeficiency: UK experience
- Mohamed Najib Mohamed Unni, Reem Elfeky, Kanchan Rao, Zohreh Nademi, Robert Chiesa, Persis Amrolia, Roderick Skinner, Olga Slater, Austen Worth, Terence Flood, Mario Abinun, Sophie Hambleton, Waseem Qasim, Hubert B. Gaspar, Andrew J. Cant, Andrew R. Gennery, Paul Veys, Mary A. Slatter
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?